for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Ltd (ADR)

TEVA.N

Latest Trade

9.51USD

Change

-0.31(-3.16%)

Volume

3,069,143

Today's Range

9.49

 - 

9.81

52 Week Range

6.25

 - 

13.76

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Teva Pharmaceutical Industries Q3 GAAP Loss Per Share $3.97

Nov 5 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.58.Q3 GAAP LOSS PER SHARE $3.97.Q3 REVENUE $4.0 BILLION.FULL YEAR 2020 BUSINESS OUTLOOK REVISED.SEES FY NET REVENUES OF $16.5-$16.8 BILLION.SEES FY EPS OF $2.40 - $2.55.TEVA PHARMACEUTICAL - GENERIC PRODUCTS REVENUES IN NORTH AMERICA SEGMENT (INCLUDING BIOSIMILARS) IN Q3 OF 2020 WERE $928 MILLION, AN INCREASE OF 2%.TEVA PHARMACEUTICAL INDUSTRIES - COPAXONE REVENUE IN NORTH AMERICA SEGMENT IN Q3 OF 2020 DECREASED BY 13% TO $236 MILLION, COMPARED TO THIRD QUARTER OF 2019.AS OF SEPTEMBER 30, 2020, OUR DEBT WAS $25,621 MILLION, COMPARED TO $26,266 MILLION AS OF JUNE 30, 2020.

Collegium Announces Settlement With Teva Resolving Xtampza Er Patent Litigation

Sept 30 (Reuters) - Collegium Pharmaceutical Inc <COLL.O>::COLLEGIUM ANNOUNCES SETTLEMENT WITH TEVA RESOLVING XTAMPZA ER PATENT LITIGATION.COLLEGIUM - REACHED A SETTLEMENT AGREEMENT WITH TEVA PHARMACEUTICAL USA.COLLEGIUM - WILL GRANT TEVA A LICENSE TO MARKET ITS GENERIC VERSION OF XTAMPZA ER IN THE UNITED STATES BEGINNING ON OR AFTER SEPTEMBER 2, 2033.COLLEGIUM - TEVA AGREED TO CONSENT JUDGMENT CONFIRMING ITS PROPOSED GENERIC PRODUCTS INFRINGE CO'S ASSERTED PATENTS & THAT THOSE PATENTS ARE VALID.COLLEGIUM - ADDITIONAL DETAILS REGARDING THE SETTLEMENT ARE CONFIDENTIAL..

Alkermes Files Lawsuit Against Teva USA & Teva Pharmaceutical Industries

Sept 9 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES PLC - CO'S UNITS FILED PATENT INFRINGEMENT LAWSUIT IN U.S. DISTRICT COURT AGAINST TEVA USA & TEVA PHARMACEUTICAL INDUSTRIES LTD.ALKERMES - LAWSUIT FILED IN RESPONSE TO TEVA USA’S NOTICE LETTER REGARDING ANDA SUBMITTED RELATED TO GENERIC VERSION OF VIVITROL IN U.S..ALKERMES - TEVA USA'S NOTICE LETTER ALLEGES ’499 PATENT IS INVALID, UNENFORCEABLE AND/OR WILL NOT BE INFRINGED BY TEVA USA’S PROPOSED PRODUCT.ALKERMES - TEVA USA'S NOTICE LETTER REFERENCED PARAGRAPH IV CERTIFICATION AGAINST ONE ALKERMES PATENT RELATED TO VIVITROL ('499 PATENT).

Teva Pharma Finance Netherlands Offering To Exchange Upto €1 Bln Of 6% Senior Notes

Aug 17 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA PHARMA FINANCE NETHERLANDS - OFFERING TO EXCHANGE UPTO €1 BILLION OF 6% SENIOR NOTES DUE 2025 FOR EQUAL AMOUNT OF OUTSTANDING 6% SENIOR NOTES DUE 2025.TEVA PHARMA FINANCE NETHERLANDS - OFFERING TO EXCHANGE UPTO $1 BILLION OF 7.125% SENIOR NOTES DUE 2025 FOR EQUAL AMOUNT OF OUTSTANDING 7.125% SENIOR NOTES DUE 2025.

Teva Reports Q2 Revenue Of $3.9 Bln

Aug 5 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $0.55.Q2 GAAP EARNINGS PER SHARE $0.13.Q2 REVENUE $3.9 BILLION.FULL YEAR 2020 BUSINESS OUTLOOK REAFFIRMED.SAYS AS OF JUNE 30, 2020, DEBT WAS $26,266 MILLION, COMPARED TO $26,103 MILLION AS OF MARCH 31, 2020.QTRLY REVENUES FROM NORTH AMERICA SEGMENT IN Q2 OF 2020 WERE $2,047 MILLION, A DECREASE OF $24 MILLION, OR 1%.TEVA PHARMACEUTICAL INDUSTRIES - QTRLY GENERIC PRODUCTS REVENUES IN NORTH AMERICA SEGMENT (INCLUDING BIOSIMILARS) IN Q2 $923 MILLION, DOWN 2%.COPAXONE REVENUES IN EUROPE SEGMENT IN Q2 2020 DECREASED BY 21% TO $84 MILLION, VERSUS Q2 2019.QTRLY AJOVY REVENUES IN NORTH AMERICA SEGMENT IN Q2 OF 2020 WERE $34 MILLION, AN INCREASE OF $11 MILLION, OR 50%.QTRLY COPAXONE REVENUES IN NORTH AMERICA SEGMENT IN Q2 OF 2020 DECREASED BY 13% TO $238 MILLION.

Teva Announces New Strategic Focus In The Japanese Market

July 30 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA ANNOUNCES NEW STRATEGIC FOCUS IN THE JAPANESE MARKET.TEVA PHARMACEUTICAL INDUSTRIES LTD - WILL DIVEST MAJORITY OF CURRENT NON-DIFFERENTIATED GENERICS PORTFOLIO, AS WELL AS LOCAL MANUFACTURING.TEVA PHARMACEUTICAL INDUSTRIES LTD - SHIFT WILL INCLUDE A DIVESTMENT OF MAJORITY OF BV'S GENERIC AND OPERATIONAL ASSETS TO NICHI-IKO PHARMACEUTICAL CO.TEVA - BV WILL RETAIN ABOUT 20 GENERIC MOLECULES & SEVERAL PIPELINE ASSETS, AS WELL AS ITS PORTFOLIO OF AUTHORIZED GENERICS, LLPS & SPECIALTY ASSETS.

FDA Says Teva Recalling 14 Lots Of Metformin Hydrochloride Extended-Release Tablets

June 5 (Reuters) - :US FDA SAYS TEVA RECALLING 14 LOTS OF METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, USP 500 MG AND 750 MG, DUE TO DETECTION OF EXCESS NDMA LEVELS.

National Institutes Of Health Begins Clinical Trial Of Hydroxychloroquine And Azithromycin To Treat Covid-19

May 14 (Reuters) - National Institutes Of Health: :NATIONAL INSTITUTES OF HEALTH BEGINS CLINICAL TRIAL OF HYDROXYCHLOROQUINE AND AZITHROMYCIN TO TREAT COVID-19.TEVA PHARMACEUTICALS IS DONATING MEDICATIONS FOR PHASE 2B STUDY ENROLLING ADULTS WITH MILD TO MODERATE COVID-19 IN U.S. .PHASE 2B TRIAL WILL ENROLL APPROXIMATELY 2,000 ADULTS AT PARTICIPATING AIDS CLINICAL TRIALS GROUP.PARTICIPANTS IN ACTG STUDY, CALLED A5395, WILL RECEIVE ORAL MEDICATIONS TO TAKE AT HOME .PARTICIPANTS WILL RECORD THEIR SYMPTOMS, ADHERENCE TO TREATMENT, AND MAJOR EVENTS SUCH AS HOSPITALIZATIONS IN A DIARY FOR 20 DAYS.PARTICIPANTS RANDOMLY ASSIGNED TO EXPERIMENTAL GROUP WILL TAKE 400 MG OF HYDROXYCHLOROQUINE TWICE ON DAY 1, 200 MG TWICE DAILY FOR ADDED 6 DAYS.

Teva Reports Q1 Non-GAAP Earnings Per Share $0.76

May 7 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $0.76.Q1 GAAP EARNINGS PER SHARE $0.06.Q1 REVENUE $4.4 BILLION.FULL YEAR 2020 BUSINESS OUTLOOK REAFFIRMED.FULL YEAR 2020 BUSINESS OUTLOOK REAFFIRMED.REVENUES FROM NORTH AMERICA SEGMENT IN Q1 OF 2020 WERE $2,082 MILLION, AN INCREASE OF $36 MILLION.GENERIC PRODUCTS REVENUES IN OUR NORTH AMERICA SEGMENT IN Q1 WERE $952 MILLION, DOWN 1% COMPARED TO Q1 2019.COPAXONE REVENUES IN NORTH AMERICA SEGMENT IN Q1 OF 2020 DECREASED BY 5% TO $198 MILLION, COMPARED TO Q1 OF 2019.GENERIC PRODUCTS REVENUE IN NORTH AMERICA SEGMENT IN QUARTER DOWN 1% TO $952 MILLION.COPAXONE REVENUE IN NORTH AMERICA IN QUARTER DOWN 5% AT $198 MILLION.AUSTEDO REVENUES IN N. AMERICA SEGMENT IN Q1 INCREASED BY 64% TO $122 MILLION, COMPARED TO $74 MILLION IN Q1 OF 2019.AS OF MARCH 31, 2020, OUR DEBT WAS $26,103 MILLION, COMPARED TO $26,908 MILLION AS OF DECEMBER 31, 2019.TEVA PHARMACEUTICAL- DECREASE IN DEBT WAS MAINLY DUE TO REPAYMENT AT MATURITY OF $700 MILLION 2.25% SENIOR NOTE SENIOR NOTES, EXCHANGE RATE FLUCTUATIONS.IMPAIRMENT OF LONG-LIVED ASSETS OF $724 MILLION IN QUARTER.

Teva And Celltrion Healthcare Announce Launch Of TRUXIMA Injection

May 4 (Reuters) - Celltrion HealthCare Co Ltd <091990.KQ>::TEVA AND CELLTRION HEALTHCARE ANNOUNCE LAUNCH OF TRUXIMA® (RITUXIMAB-ABBS) INJECTION FOR RHEUMATOID ARTHRITIS, ONLY BIOSIMILAR TO RITUXAN® (RITUXIMAB) AVAILABLE IN UNITED STATES FOR THIS INDICATION.TEVA PHARMACEUTICAL INDUSTRIES LTD - TRUXIMA IS NOW AVAILABLE FOR TREATMENT OF GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up